| Bioactivity | Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research. |
| Invitro | Atezolizumab (0, 2.5, 5, 10, 20, and 40 µg/ml; 24 hours; HOS and 143B cells) inhibits proliferation and induces immune-independent apoptosis of osteosarcoma cells[1].Atezolizumab impairs the function of mitochondria to cause the imbalance between oxidants and antioxidants. Atezolizumab induces mitochondria-related apoptosis of osteosarcoma cells by activating JNK pathway. Atezolizumab (10 µg/ml; 24 hours; HOS and 143B cells) induces autophagy in osteosarcoma cells[1]. |
| Name | Atezolizumab |
| CAS | 1380723-44-3 |
| Molar Mass | 144590.50 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |